Bayer HealthCare

Top Story

Intendis and Kythera launch cooperation in aesthetic dermatology segment

Bayer HealthCare’s dermatology business Intendis and KYTHERA Biopharmaceuticals have signed a licensing and development agreement to jointly develop a new adipolytic agent (ATX-101). The first-in-class drug is designed to reduce localized fat under the chin after being injected. more

Revolution in the bedroom

The little tablet was as big as a lentil and as green as a pea: At the beginning of the 1960s, Bayer Schering Pharma launched Anovlar®, its first oral contraceptive, in Europe and Australia. Packed in silvery aluminium foil, the “anti-baby” pill allowed women for the first time to enjoy their sexuality and to decide themselves whether they would like to have children and, if so, when and how many. Neither Einstein’s theory of relativity nor the Internet has influenced the world and modern society like this medical innovation. This year, the pill celebrates its 50th anniversary. more

Renal Cancer Journalists’ Award 2011

Renal cell carcinoma is one of the most common cancers worldwide. However, there still is a lack of awareness of the disease. Bayer HealthCare and the Kidney Cancer Association (KCA) have therefore announced the European “Advances in Renal Cancer” Journalists’ Award 2011. The prize honors journalistic work, in which journalists cover the issue of renal cancer in a critical, but yet objective manner.

mehr

The miracle drug

Verdi’s famous opera La traviata and Aspirin® have one thing in common: both of them had their first major appearance on March 6. Giuseppe Verdi celebrated the premiere of his masterpiece in Venice in 1853, while Bayer’s Aspirin® brand was registered under number 36433 in the list of trade names at the Imperial Patent Office in Berlin in 1899. While the opera initially flopped and only later brought its composer fame and fortune, the drug of the century went from strength to strength from the very first day and celebrated an unparalleled career. more

Elder couple embracing each other at the beach

Improving men’s health care

In April, Bayer Schering Pharma hosted a media roundtable “New insight into safety and effectiveness of testosterone therapy” at the 25th Annual Congress of the European Association of Urology (EAU) in Barcelona, Spain. The press event highlighted the importance and low awareness of Testosterone Deficiency Syndrome (TDS) in men. A select number of medical journalists viewed presentations by experts in the TDS and Erectile Dysfunction (ED) field and enjoyed the opportunity to interact with them and ask critical questions. more

Mastering MS – patients need support

Treating multiple sclerosis means more than just optimizing existing therapies, but also offering physicians and patients support and a complete help network including the latest information about the disease. To raise awareness for the broad and deep impact MS can have, Bayer Schering Pharma has developed a global campaign called “Mastering MS”. It educates about the visible and hidden symptoms of MS, the importance of early treatment as well as seeking additional help if needed. more

ACT Study 2009

New data confirming the serious health and economic consequences of aspirin underutilization in the prevention of cardiovascular disease (CVD) were presented at a press conference held by Bayer Schering Pharma at the ESC Congress 2009. Experts discussed new results from the ACT study in the context of other recent research on low-dose aspirin in the prevention of CVD, and emphasized the need to broaden the use of aspirin therapy to help reduce the global burden of deaths and disability due to CVD. more

European Nutritionals Press Workshop

European adults and adolescents often do not get the essential vitamins and minerals needed from their diet, even if it is well-balanced. This is the consensus shared by scientists in the field of micronutrient research, who came together in April 2009 at the university of Madrid for the first European Nutritionals Press Workshop organized by Bayer HealthCare. The experts provided more than 50 media representatives from fifteen European countries with an update on current micronutrient research. more

Diabetes – a widespread disease

Diabetes is becoming more and more widespread. According to figures of the IDF about 285 million people suffer from the chronic metabolic disorder worldwide. In Germany, it is assumed that about eight million people are concerned – and experts notice an upward trend. Nevertheless, many people know little about their illness as it does not hurt. But the consequences can be dramatic. How can you live with diabetes, what can you do, what should you do, and what must you do to maintain your quality of life and to prevent late complications? more

Healthcare News
Country News
International Events
Service Material

Healthcare News

2010-08-31 | Exclusively for medical journalists

2010-08-31 | Exclusively for medical journalists
TALENT Study Shows: Starting with a Combination of Adalat® GITS and Pritor®/Kinzal® Achieves Earlier Blood Pressure Control than Initiating Monotherapy with Either Combination Component

First study ever to examine blood pressure-lowering efficacy of the combination of nifedipine (Adalat® GITS) with telmisartan (Pritor®/Kinzal®) more
2010-08-31 | Thrombosis

2010-08-31 | Thrombosis
Bayer´s Rivaroxaban Successfully Meets Primary Efficacy Outcome and Demonstrates Similar Safety to Standard Therapy in Phase III EINSTEIN-DVT Non-Inferiority Study

Results from EINSTEIN-DVT Study Presented at European Society of Cardiology Congress 2010 more
2010-08-30 | Worldnews

2010-08-30 | Worldnews
Intendis and KYTHERA Enter Licensing and Development Agreement on Adipolytic Agent for Aesthetic Dermatology Use

Bayer’s dermatology subsidiary Intendis prepares to enter aesthetics segment / Joint development of first-in-class injectable drug for minimally invasive facial fat reduction more

More news

Country News

News from

2010-07-26 |

2010-07-26
Caution during the “hot months” – Spanish awareness campaign on contraception provides information online

In Spain, a national awareness campaign on contraception supported by Bayer HealthCare calls for more action to address the problem of unplanned pregnancies and the infection with sexually transmitted diseases. more
2009-11-06 |

2009-11-06
Experts Warn of Risk from Changing Parasite Trends in Asia Pacific

Second meeting of the Canine Vector-Borne Diseases (CVBD) and Parasitic Zoonosis Asia Pacific Forum more
2009-09-23 |

2009-09-23
Press Conference “World Contraception Day 2009“

On September 26, 2009, more than 70 countries were involved in educational activities and events to mark “World Contraception Day”. The campaign which is sponsored by Bayer Schering Pharma calls for more action to address the burgeoning problem of unplanned pregnancies. more
2009-09-11 |

2009-09-11
World Heart Day 2009

To help promote improved health and productivity in the workplace environment, Bayer HealthCare teamed up again with the World Heart Federation to promote World Heart Day 2009 themed “Work with Heart.” more
2009-08-05 |

2009-08-05
New therapeutic option for heartburn

Bayer Consumer Care New Zealand will launch omeprazole under the Losec® brand without prescription / Bayer will market OTC omeprazole based on an exclusive licensing agreement with AstraZeneca more

More healthcare news

International Events

ESC Congress 2010 in Stockholm, Sweden, August 28 - September 1

The ESC Congress currently is the largest cardiovascular medicine meeting in the world. The congress takes place at the end of August over five days in 30 lecture rooms. It convenes all disciplines and delegates come from 150 different countries. more
WCGIC - 12th World Congress on Gastrointestinal Cancer in Barcelona, Spain, June 30 - July 3

In its twelfth year, and endorsed by leading professional societies and organizations, the Congress is the premier global event in the field, encompassing malignancies affecting every component of the gastrointestinal tract and aspects related to the care of patients with gastrointestinal cancer, including screening, diagnosis and the latest management options for common and uncommon tumors. With the focus on personalized therapy, multidisciplinary management and unraveling molecular mechanisms, this event will educate and update the broad range of experts who participate in the treatment of gastrointestinal cancers, providing a clear overview for treatment. more
ESSO - 15th Congress of the European Society of Surgical Oncology, September 15 - 17

The European Society of Surgical Oncology, ESSO, was founded in 1981 to advance the art, science and practice of surgery for the treatment of cancer. The general theme for the 2010 Congress is "Surgical outcome: can we do better?" The Congress format is designed to promote the highest standards of surgical care in the management of patients with solid tumours. This is the ideal connective platform to exchange and debate the very latest in patient treatment and care as well as novel approaches to surgical care in a rapidly changing health care environment. more

viva.vita event calendar

Service Material

New edition of “Names, Figures, Facts”

The updated 2010/2011 edition of the booklet “Names, Figures, Facts” contains the most important information about the Bayer Group in a clearly structured, easy-to-read format. more
MS-Gateway offers up-to-date information for patients with multiple sclerosis

In the field of multiple sclerosis, Bayer Schering Pharma has been a pioneer with a long-term commitment and a declared goal: to optimize the support of patients with MS. The Internet portal www.ms-gateway.com is an international community focusing on multiple sclerosis, which offers thousands of patients an informative, web-based tool for up-to-date information and resources to manage the disease. more
Database offers information about clinical studies

The Bayer HealthCare “Clinical Trials Registry and Results Database Website” contains information on clinical trials sponsored by Bayer, and is provided for patients and health care professionals to increase the transparency of the company’s scientific research. more